ReviewCarcinogenesis2015
SATB1 and 2 in colorectal cancer.
Review in Carcinogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- SATB1 overexpression correlates with gastrointestinal neoplasms invasion and metastasis: a meta-analysis for Chinese population.Oncotarget · 2017Pooled it
- The multifaceted role of microRNAs in colorectal cancer: pathogenesis and therapeutic implications.Non-coding RNA research · 2025Review
- Advances in research on SATB2 and its role in tumor development.Cell & bioscience · 2025Review
- Elevated Methylation Contributes to Suppressed Expression of Special AT-Rich Sequence-Binding Protein 2 in Colorectal Cancer: A Gene-Disease Association Study.Health science reports · 2025Article
- Reduced Expression of SATB2 in Colorectal Cancer and Its Association with Demographic and Clinicopathological Parameters.International journal of molecular sciences · 2025Article
- Article
- Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.Virchows Archiv : an international journal of pathology · 2022Article
- SATB1-mediated chromatin landscape in T cells.Nucleus (Austin, Tex.) · 2020Review
- Transcriptomic Profiling of Tumor-Infiltrating CD4Vaccines · 2020Article
- Long Non-Coding RNA ELFN1-AS1 Promoted Colon Cancer Cell Growth and MigrationFrontiers in oncology · 2020Article
- SATB2 and NGR1: potential upstream regulatory factors in uterine leiomyomas.Journal of assisted reproduction and genetics · 2019Article
- Article
- The Role of Ubiquitination in Regulating Embryonic Stem Cell Maintenance and Cancer Development.International journal of molecular sciences · 2019Review
- Deregulation of SATB2 in carcinogenesis with emphasis on miRNA-mediated control.Carcinogenesis · 2019Review
- Review
- The expression of special AT-rich binding protein 1 in cervical cancer and its clinical significance.OncoTargets and therapy · 2019Article
- Role of miR-31 and SATB2 in arsenic-induced malignant BEAS-2B cell transformation.Molecular carcinogenesis · 2018Article
- SATB2 targeted by methylated miR-34c-5p suppresses proliferation and metastasis attenuating the epithelial-mesenchymal transition in colorectal cancer.Cell proliferation · 2018Article
- Prognostic and Clinicopathological Significance of SATB1 in Colorectal Cancer: A Meta-Analysis.Frontiers in physiology · 2018Article
- miR-449a inhibits colorectal cancer progression by targeting SATB2.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The special AT-rich sequence-binding proteins 1 and 2 (SATB1/2) are nuclear matrix associated proteins that are transcription factors involved in chromatin remodeling and gene regulation. Expression of the SATB2 gene is tissue-specific, and the only epithelial cells expressing SATB2 are the glandular cells of the lower gastrointestinal tract where its expression is regulated by microRNA-31 (miR-31) and miR-182. SATB2, along with its homolog SATB1, are thought to be involved in various cancers with their roles in this disease being specific to the type of cancer. Colorectal cancer (CRC) provides the largest association of SATB2 with cancer and the roles of SATB2 are better defined and more studied in CRC than in any other cancer type. SATB1 displays a negative association with SATB2 in CRC. The various studies that have investigated the involvement of SATB1 and 2 in CRC have produced consistent findings. Here, we form four major conclusions regarding the role of these proteins in CRC and their potential clinical value: (i) SATB2 is a sensitive marker to distinguish CRC from other cancer types, (ii) Reduced expression of SATB2 in CRC is associated with poor prognosis, (iii) High levels of SATB1 expression facilitate CRC and are associated with poor prognosis and (iv) Overexpression of miR-31 and -182 in CRC leads to more aggressive cancer. This review will describe several of the key investigations that established these conclusions and highlight results that offer opportunities for future research in the treatment and diagnosis of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.